Search

IMM-101

IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

Coronavirus-Like Particle COVID-19 Vaccine

A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged … The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection.

RUTI® Vaccine

Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).

ARCoV

SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. … Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week.

Buthiazide

Cetyltrimethylammonium naproxenate

Methylisothiazolinone

XAV-19

As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558].

Etesevimab

Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.

Fenchone